News

The deal will see Recro Pharma secure worldwide rights to IV/IM meloxicam and also a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia, US. IV/IM meloxicam

The deal will see advancement of an alternative delivery method for Pfenex’s Px563L-mrPA, using Glide’s solid dose formulation technology. The contract extension is the result of the National

RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications whose active ingredient is Thymosin beta 4 (TB4). The company will receive a $5.92m investment from Global

Under the deal, Concordia will buy substantially all of the commercial assets of Covis Pharma and Covis Injectables, including 18 branded and authorized generic products. Covis drug portfolio

The Emergent-developed MOR209/ES414 molecule is an immunotherapeutic protein, which has shown in preclinical in vitro and in vivo studies its ability to redirect T-cell cytotoxicity towards cells expressing

Sandoz, a Novartis company, is the first in the US to receive the approval through the new FDA biosimilars pathway established under the Biologics Price Competition and Innovation

The companies will conduct a study assess the clinical accuracy of spectral imaging technology with low radiation dose to measure breast density, potentially increasing accuracy of cancer detection

The anti-blood clotting drug apixaban can be used to treat venous thromboembolism (VTE) in adults, which is used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE).

People familiar with the matter were reported by Reuters as saying that GSK confirmed the dismissal was for wrongdoing and misconduct that took place before mid-2013. However, the